• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Pfizer Teams Up with Sickle Cell Disease Community to Launch New Online Platform

Pfizer Inc. today announced the launch of oneSCDvoice, a collaborative digital platform that provides access to resources designed to increase knowledge, emotional support, and help empower people living with sickle cell disease (SCD). Developed in collaboration with SCD patients, advocates, and medical experts, oneSCDvoice offers access to disease education from multiple sources, information about clinical trials, and includes an online social wall for community conversations.

SCD is a lifelong and debilitating disorder that affects red blood cells. In SCD, blood and oxygen flow are restricted, which causes sudden, severe pain, can lead to organ damage, and can shorten life spans. SCD affects approximately 100,000 people in the United States and is therefore considered a rare disease. A number of misunderstandings about the disease exist, underscoring the need for educational resources that increase awareness and provide a forum for those affected to connect with each other.